How does Osimertinib tablets work?

Osimertinib tablets, also known asAZD-9291 or osimertinib mesylate tablets, is a highly efficient and selective EGFR mutant inhibitor for non-small cell lung cancer (NSCLC). Its therapeutic effect is remarkable and brings hope to many lung cancer patients.

Osimertinib tablets can specifically inhibitEGFR mutations, thereby blocking the growth, proliferation and metastasis of tumor cells. This mechanism of action enables Osimertinib tablets to achieve significant therapeutic effects in the treatment of non-small cell lung cancer patients carrying EGFR sensitive mutations or T790M resistant mutations.

In clinical trials, the performance of osimertinib tablets is impressive. It can significantly extend the progression-free survival (PFS) and overall survival (OS) of patients, and improve the quality of life of patients. At the same time, osimertinib tablets also show good efficacy in patients with brain metastases, able to penetrate the blood-brain barrier and provide good control of brain and meningeal lesions.

Osimertinib tablets also performed well in comparison with other targeted drugs for lung cancer. Compared with first-generation targeted drugs such as Iressa and Tarceva, osimertinib tablets show advantages in terms of efficacy and side effects. It can more effectively control the growth and spread of tumors while reducing the incidence of side effects for patients.

Osimertinib tablets also have certain limitations. Long-term use may induce drug resistance, leading to a gradual reduction or inefficiency of treatment effects. In addition, osimertinib tablets may also produce some adverse reactions during use, such as rash, diarrhea, cough, etc. Therefore, when using osimertinib tablets for treatment, it is necessary to closely monitor the patient's condition changes and adverse reactions, and adjust the treatment plan in a timely manner according to the patient's specific situation.